



Antibiotic Therapy Optimization in Special Populations

Guest Editors:

Dr. Eun Kyoung Chung

Division of Clinical
Pharmacy/Infectious Diseases
Pharmacotherapy, Department
of Pharmacy, College of
Pharmacy, Kyung Hee University,
Seoul, Korea

Prof. Dr. Sara K. Quinney

Department of Obstetrics and
Gynecology and Division of
Clinical Pharmacology,
Department of Medicine, Indiana
University School of Medicine,
Indianapolis, IN, USA

Deadline for manuscript
submissions:
closed (30 September 2022)

Message from the Guest Editors

Dear Colleagues,

Individualized precision antibiotic therapy is critical to optimize treatment outcomes because sufficient antimicrobial concentrations are imperative to achieve maximal killing activity. However, the design of optimal individualized antibiotic therapy regimen is particularly complicating for the patient populations whose gradual or acute pathophysiologic alterations substantially impact antimicrobial pharmacokinetics and pharmacodynamics. These patient populations are collectively called *special populations* and include critically ill patients, elderly populations, obese individuals, etc.

In this Special Issue, scientific advances in designing optimal antibiotic therapy considering various patient characteristics will be discussed focusing on the aforementioned special patient populations. The multidisciplinary efforts in the field of antibiotic pharmacotherapy will provide insight for clinician scientists and healthcare professionals regarding the optimal antimicrobial therapy for special patient populations.

Keywords: clinical pharmacometrics; PK/PD optimization of antibiotic therapy; special populations





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi